Clinical trials
22 active studies led by ImmunityBio, Inc., of 83 in all
Source: ClinicalTrials.gov, Studies with ImmunityBio, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 7Markets in public records
- 0Regions & countries
- 22Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by ImmunityBio, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on ImmunityBio, Inc.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Company facts
- Stock listing
- NASDAQ: IBRX
- Type
- Medicines
Source: SEC EDGAR, Company filings, CIK 1326110. Retrieved 13 Nov 2026.
See them on ClinicalTrials.gov (opens in a new tab)
SEC filings
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1326110.
Trials over time
Studies ImmunityBio, Inc. leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with ImmunityBio, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show ImmunityBio, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets ImmunityBio, Inc. is in.
From our blog
Stories on the topics ImmunityBio, Inc. works in.
Brain Cancer Diagnosis: Imaging and New Biomarkers
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Bioinformatics: Making Sense of Health Data
Sequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics…
Read
Dermatology Diagnostics: AI and Skin Health
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read